Monday, May 23, 2022
No Result
View All Result
Medical Finance
  • Home
  • News
  • Interviews
  • Mediknowledge
  • Insights From Industry
  • Thought Leaders
  • Coronavirus
  • Whitepapers
  • Home
  • News
  • Interviews
  • Mediknowledge
  • Insights From Industry
  • Thought Leaders
  • Coronavirus
  • Whitepapers
No Result
View All Result
Medical Finance
No Result
View All Result
Home Coronavirus

Antibody response 18 months after SARS-CoV-2 infection in vaccinated and unvaccinated individuals

by Medical Finance
in Coronavirus
Study: Long-Term Persistence of IgG Antibodies in recovered COVID-19 individuals at 18 months and the impact of two-dose BNT162b2 (Pfizer-BioNTech) mRNA vaccination on the antibody response. Image Credit: Kateryna Kon/Shutterstock
9
SHARES
104
VIEWS
Share on FacebookShare on Twitter

Several severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants have emerged since the coronavirus disease 2019 (COVID-19) pandemic. These variants can be combated by thoroughly evaluating the long-term efficacy of immune response in both the vaccinated and recovered individuals. The World Health Organization’s (WHO) campaign for Vaccine Equity is a global challenge to ensure equal allocation of vaccines across all countries. Several recent studies have reported that post-infection immunity is long-acting, durable, and protective.


Study: Long-Term Persistence of IgG Antibodies in recovered COVID-19 individuals at 18 months and the impact of two-dose BNT162b2 (Pfizer-BioNTech) mRNA vaccination on the antibody response. Image Credit: Kateryna Kon/ShutterstockStudy: Long-Term Persistence of IgG Antibodies in recovered COVID-19 individuals at 18 months and the impact of two-dose BNT162b2 (Pfizer-BioNTech) mRNA vaccination on the antibody response. Image Credit: Kateryna Kon/Shutterstock


Individuals who have recovered from COVID-19 infections are advised to undergo a complete vaccination similar to naïve individuals who have no previous history of infection. However, whether two doses of the vaccine are required for recovered individuals or one dose would be sufficient is still questionable.


Real-time data have indicated that a single dose of vaccine can adequately enhance immunity in recovered individuals who have protective immunity compared to a double dose. However, ideal vaccine dosing regimens or recall responses have not been studied in recovered individuals.


Studies suggest that vaccination can elicit a more specific and higher magnitude response focused on the spike-receptor binding domain (S-RBD) instead of the Nucleocapsid (NCP) as compared to natural infection.


A new study published in the pre-print server medRxiv* assessed the dynamics of IgG titers over 18 months in patients who had recovered from COVID-19 infections during March 2020. The study also investigated the impact of two doses of the BNT162b2 (Pfizer-BioNTech) vaccination on the antibody titers of these patients as compared to those patients who had not received any dose of the vaccine.


About the study


The study involved patients based in the Umbria region of Italy who had tested positive for SARS-CoV-2 by real-time polymerase chain reaction reverse transcription (RT-qPCR). The patients had to fill out a questionnaire to provide information regarding their COVID-19 related clinical history, symptoms, and treatment undertaken. Also, blood samples were collected from those patients recruited in the study.


The antibody titers of the patients were analyzed from May 2020 to January 2021. The first blood sample collected in May 2020 after infection in March 2020 was defined as T0. After that, the samples were analyzed at three months (T1), five months (T2), seven months (T3), eight months (T4), and ten months (T5) post-infection.


The study participants were divided into two groups, group A comprised of recovered patients vaccinated with two doses of the BNT162b2 vaccine, and group B comprised unvaccinated recovered patients. The presence of anti-S-RBD antibodies was analyzed from February 2021 to September 2021 in both groups. Also, detection of anti-NCP antibody was carried out for group B to determine the persistence of infection-induced immunity that was not generated by vaccination.


Study findings


The results indicate that a double dose vaccination in recovered individuals had a major impact on the antibody titers. The antibody titers were found to increase rapidly post-vaccination, but the rise was short-lived, which explains the importance of boosters. The IgG titers were reported to increase 161 times while the IgM titers increased by an amount of 0.773.


However, unvaccinated recovered individuals were found to test positive for anti-S-RBD antibodies 18 months post-infection. No cases of reinfection were reported in these individuals despite the emergence of multiple mutant strains that brought about several waves of infection. Most recovered individuals also tested positive for anti-NCP antibodies at 18 months post-infection.


Therefore, the current study demonstrates that immunity conferred by SARS-CoV-2 infection lasted longer as compared to vaccination. Although the antibodies are boosted significantly post-vaccination, this response is short-lived. Also, testing for anti-NCP antibodies can help analyze the type of existing immunity in an individual. Further research is required to determine the dose regimen and timing of vaccination to ensure adequate immune response in an individual.


Limitations


The study had certain limitations. First, the sample size of the study was small. Second, simultaneous antibody titer assessment for both NCP and S-RBD would have given better results for the comparative analysis. However, the S-RBD assay received emergency approval in late 2020.


*Important notice


medRxiv publishes preliminary scientific reports that are not peer-reviewed and, therefore, should not be regarded as conclusive, guide clinical practice/health-related behavior, or treated as established information.

Total
0
Shares
Share 0
Tweet 0
Pin it 0
Share 0
Medical Finance

Medical Finance

Related Posts

How accurate are rapid antigen COVID tests?

How accurate are rapid antigen COVID tests?

by Medical Finance
May 23, 2022
0

A new study updates the state of knowledge about antigen rapid diagnostic tests (Ag-RDT) in the diagnosis of coronavirus disease...

Study: Protection against SARS-CoV-2 after Covid-19 Vaccination and Previous Infection. Image Credit: Tanya Antusenok/Shutterstock

Study characterizes COVID-19 vaccine effectiveness at longer dose intervals

by Medical Finance
May 23, 2022
0

In a recent study published in the New England Journal of Medicine, researchers conducted a prospective cohort study in the UK to...

Study: Longitudinal monitoring of SARS-CoV-2 neutralizing antibody titers and its impact on employee personal wellness decisions. Image Credit: Huen Structure Bio/Shutterstock

Study examines whether knowledge of virus-neutralizing antibody titer impacted wellness decision-making

by Medical Finance
May 23, 2022
0

In a recent study posted to the medRxiv* preprint server, researchers evaluated the impact of virus-neutralizing antibody (vnAb) titers against severe...

Study: The Efficacy of Common Household Cleaning Agents for SARS-CoV-2 Infection Control. Image Credit: Alexander Raths / Shutterstock.com

How effective are household cleaning agents against SARS-CoV-2?

by Medical Finance
May 23, 2022
0

The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the causal agent of the coronavirus disease 2019 (COVID-19), belongs to the...

Study: Evaluation of “test to return” after COVID-19 diagnosis in a Massachusetts public school district. Image Credit: Michele Ursi / Shutterstock.com

COVID test-to-return may help shorten time away from school

by Medical Finance
May 23, 2022
0

The ongoing coronavirus disease 2019 (COVID-19) pandemic led to the exodus of millions upon millions of students from schools worldwide,...

Study: A live-attenuated SARS-CoV-2 vaccine candidate with accessory protein deletions. Image Credit: Pixza Studio/Shutterstock

Study reports a highly attenuated SARS-CoV-2 that could serve as a live-attenuated vaccine platform

by Medical Finance
May 23, 2022
0

Coronavirus disease 2019 (COVID-19) vaccination platforms have been generated unprecedentedly. Live-attenuated severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccines have...

Next Post
Study: The changing impact of vaccines in the COVID-19 pandemic. Image Credit: Ramcreative / Shutterstock.com

Impact of new COVID vaccinations as novel variants emerge

Scientists discover antibody that inhibits a broad range of sarbecoviruses

Breakthrough infection could provide broad protection against current SARS-CoV-2 variants of concern

0 0 votes
Article Rating
Subscribe
Login
Notify of
guest
guest
0 Comments
Inline Feedbacks
View all comments

Support

  • Contact
  • Disclaimer
  • Home
  • Privacy Policy
  • Terms And Conditions

Categories

  • Coronavirus
  • Insights From Industry
  • Interviews
  • Mediknowledge
  • News
  • Thought Leaders
  • Whitepapers

More News

  • Study: Post-Acute COVID-19 Syndrome (PACS) in Adults. Image Credit: Josie Elias/Shutterstock
    Study explores long COVID in adults
  • shutterstock 1054148270 ebcc7adac18445889666f7e1f5dbad85 620x480
    Scientists elucidate the structure of central cellular inflammatory switch
  • Home
  • Privacy Policy
  • Contact
  • Disclaimer
  • Terms And Conditions

© 2022 Medical Finance - Latest Financial and Business News

No Result
View All Result
  • Interviews
  • Mediknowledge
  • News
  • Insights From Industry
  • Coronavirus
  • Thought Leaders
  • Whitepapers
wpDiscuz
0
0
Would love your thoughts, please comment.x
()
x
| Reply